Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper (Q38208808)

31 August 2017

Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper (English)

1 reference

31 August 2017

Gabriel B Habib

1

1 reference

PubMed ID

24790054

31 August 2017

Sukhdeep S Basra

series ordinal

2

1 reference

31 August 2017

1 May 2014

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

31 August 2017

1 reference

31 August 2017

19

1 reference

31 August 2017

516-525

1 reference

31 August 2017

6

1 reference

Selected major risk factors and global and regional burden of disease

31 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

21 January 2018

Vasopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Molecular and cellular mechanism of angiotensin II-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Efficacy of low-dose spironolactone in subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Effects of eplerenone versus losartan in patients with low-renin hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

PLZF and the (pro)renin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Treatment of patients with hypertension and arthritis pain: new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

The importance of blood pressure control in the patient with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibitor SLV338 Prevents Hypertensive Cardiac Remodeling in a Blood Pressure–Independent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414529620

21 January 2018

Identifiers

DOI

10.1177/1074248414529620

1 reference

31 August 2017

1 reference

PubMed ID

24790054